Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN).
Reinheit:
99.00%
CAS Nummer:
[1471999-69-5]
Target-Kategorie:
EGFR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten